XLON
IHC
Market cap23mUSD
Jul 09, Last price
19.25GBP
1D
0.00%
1Q
-11.70%
IPO
-97.93%
Name
Inspiration Healthcare Group PLC
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Inspiration Healthcare Group plc (IHC.L) is a global provider of advanced medical technology, catering to critical care, operating theatre, and home healthcare applications worldwide. The company offers a comprehensive range of products, with a strong focus on neonatal intensive care. This includes air/oxygen blenders; the Tecotherm Neo, a sophisticated servo-controlled device that precisely manages infant body temperature through continuous cooling and warming, making minute adjustments every two seconds to ensure stability; LifeStart, a bedside unit for neonatal resuscitation; and Inspire rPAP, a non-invasive, two-piece system crucial for the initial stabilization and resuscitation of infants. Beyond neonatal care, Inspiration Healthcare also supplies adult intensive care solutions, such as AlphaCore5, a patient warming system designed to prevent inadvertent hypothermia. For neonates, they provide CosyTherm2, another dedicated patient warming system for precise temperature management. Their offerings also encompass various respiratory disposables and thermoregulating products specifically for babies. In addition to its proprietary innovations, the company distributes third-party medical products, including infusion therapy items vital for parenteral feeding and chemotherapy. Inspiration Healthcare Group further enhances its services by offering technology support and supplying spare parts. Established in 1998, Inspiration Healthcare Group plc maintains its headquarters in Crawley, United Kingdom.
IPO date
Dec 14, 2001
Employees
210
Domiciled in
GB
Incorporated in
GB
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑01 | 2025‑01 | 2024‑01 | 2023‑01 | 2022‑01 | 2021‑01 | 2020‑01 | 2019‑01 | 2018‑01 | 2017‑01 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||